Cleveland BioLabs - Best Pharma Stocks of 2007
Company: Cleveland BioLabs
Starting stock price: $4.78
Ending stock price: $8.80
Percent Change: 84.10%
Details: Cleveland BioLabs is a spin-off of the famed Cleveland Clinic. The company is developing drugs using its mechanistic discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and other stresses. Cleveland BioLabs is conduction clinical trials of Curaxin CBLC102 prostate cancer, CBLC102 for renal cell carcinoma, and CBLB502 for acute radiation syndrome.
More News:
Cleveland Clinic spinoff goes public. Report
More stories about Cleveland BioLabs
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: